Biocryst Eyes Resistance Breakout as Orladeyo Revenue Forecast Hits $625–645M
BCRX•Biocryst Pharmaceuticals shares have climbed over 33% in nine of ten sessions and are set for their best week in three months testing resistance at $10.32. The company forecasts Orladeyo revenue of $625–$645 million for 2026 after 48-week data showed hereditary angioedema attacks fell to zero by week 48.
1. Technical Performance and Rally
Biocryst Pharmaceuticals shares have extended gains to six straight sessions and nine of the last ten, adding over 33% this month to reach a new 52-week high. The stock is currently testing resistance at $10.32, marking its best weekly performance in more than three months.
2. Orladeyo 48-Week Data
Updated 48-week trial data for Orladeyo in children aged 2–11 showed hereditary angioedema attacks requiring professional care fell from 22 during standard care to three in the first 12 weeks, dropping to zero between weeks 37 and 48.
3. Revenue Forecast and Pipeline Expansion
The company projects Orladeyo revenue of $625–$645 million for fiscal 2026, representing 97.7–98.4% of total revenue, and is advancing a potential Netherton syndrome treatment with Phase 1 data expected by year-end.
